Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 1, 2010, Pages

  Montaner, Julio S G ^a,b   Wood, Evan ^a,b   Kerr, Thomas ^a,b   Lima, Viviane ^a,b   Barrios, Rolando ^a   Shannon, Kate ^a,b   Harrigan, Richard ^a,b   Hogg, Robert ^a,c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Drug addiction; HIV transmission; HIV AIDS; Injection drug use; Treatment as prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BREAST FEEDING; CHILDHOOD MORTALITY; DIAGNOSTIC TEST; DRUG ABUSE; HEALTH PROGRAM; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUMAN RIGHTS; INFECTION PREVENTION; INFECTION RATE; PANDEMIC; PATIENT AUTONOMY; PATIENT COUNSELING; PRIORITY JOURNAL; PRIVACY; PUBLIC HEALTH; REVIEW; RISK REDUCTION; SEROCONVERSION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 78449293443     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f9c1f0     Document Type: Review

References (50)

1. Fauci AS. 25 years of HIV. Nature. 2008;453:289-290.
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146-154.
3. British Columbia Centre for Excellence in HIV/AIDS. Antiretroviral Therapy Guidelines. Available at: http://www.cfenet.ubc.ca/webuploads/ files/09130451-01-AdultTreatment5-2. pdf. Accessed January 4, 2009.
4. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
5. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
6. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;27: 450-454.
7. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-19.
8. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372:293-299.
9. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000;287:650-654.
10. Montaner J, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
11. Wood E, Braitstein P, Montaner J, et al. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Bull World Health Organ. 2007;85:550-554.
12. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIVepidemics? Lancet Infect Dis. 2002;2:487-493.
13. Pao D, Pillay D, Fisher M. Potential impact of early antiretroviral therapy on transmission. Curr Opin HIV AIDS. 2009;4:215-221.
14. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601.
15. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
16. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14: 415-421.
17. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997;11:1249-1254.
18. Lorello G, la Porte C, Pilon R, et al. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med. 2009;10:548-554.
19. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
20. Piot P, Bartos M, Larson H, et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet. 2008;372:845-859.
21. Attia S, Egger M, Müller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and metaanalysis. AIDS. 2009;23:1397-1404.
22. Donnell D, Kiarie J, Thomas K, et al. ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: a multinational prospective study. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16-19, 2010. Oral abstract session 40, paper 136.
23. Fang C, Hsu H, Twu S, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879-885.
24. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
25. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198:59-67.
26. Lima VD, Hogg RS, Montaner JSG. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA guidelines in British Columbia, Canada. PLOS. ONE 2010;5(6):e10991. DOI:10.1371/ journal.pone.0010991.
27. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66:769-789.
28. Wood E, Kerr T, Montaner JS. HIV treatment, injection drug use, and illicit drug policies. Lancet. 2007;370: 8-10.
29. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence based overview. Int J Drug Policy. 2007; 18:255-261.
30. Wood E, Montaner JS, Schechter MT, et al. Prevalence and correlates of untreated HIV-1 infection in the era of modern antiretroviral therapy. J Infect Dis. 2003;188:1164-1170.
31. Bruce RD, Altice FL. Clinical care of the HIV infected drug user. Infect Dis Clin North Am. 2007;21:149-179.
32. Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300: 550-554.
33. Wood E, Kerr T, Marshall B, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
34. Montaner J, Wood E, Kerr T, et al. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among injection drug users in British Columbia, Canada. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA; February 16-19, 2010. Oral abstract session 24, paper 88LB.
35. Walensky RP, Kuritzkes DR. The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIVand why it remains essential. Clin Infect Dis. 2009;50:272-276.
36. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003;912:1535-1537.
37. Currie CS, Floyd K, Williams BG, et al. Cost, affordability, and costeffectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health. 2005;12:130.
38. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIVuninfected children: a prospective cohort study. Lancet. 2008;371: 752-759.
39. Dixon S, McDonald S, Roberts J. The impact of HIV and AIDS on Africa's economic development. BMJ. 2002;324:232-234.
40. Walensky RP, Wood R, Weinstein MC, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008;197:1324-1332.
41. Volkow N, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA. 2010;303:1423-1424.
42. Gruskin S, Tarantola D. Universal access to HIV prevention, treatment and care: assessing the inclusion of human rights in international and national strategic plans. AIDS. 2008;22(Suppl 2):S123-S132.
43. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372:669-684.
44. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601.
45. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380-2382.
46. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection-2010 recommendations of the International AIDS Society- USA Panel. JAMA. 2010;304:321-333.
47. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
48. Hirsch MS. Initiating therapy: when to start, what to use. J Infect Dis. 2008;197(Suppl 3):S252-S260.
49. Sax PE, Baden LR. When to start antiretroviral therapy-ready when you are? N Engl J Med. 2009;360:1897-1899.
50. D'Agostino RB. The delayed-start study design. N Engl J Med. 2009;361: 1304-1306.